Promising prostate cancer combo trial halted early after just one patient
NCT ID NCT06388369
First seen Mar 14, 2026 · Last updated May 13, 2026 · Updated 7 times
Summary
This study tested whether giving a targeted radiation drug (LuPSMA) alone or with an immunotherapy (ipilimumab) before prostate removal surgery is safe and feasible for men with very high-risk prostate cancer. Only one participant was enrolled before the trial was terminated, so no conclusions can be drawn. The goal was to see if the treatment could shrink tumors enough to allow timely surgery and possibly improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VERY HIGH RISK PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Essen, Clinic of Urology
Essen, 45147, Germany
Conditions
Explore the condition pages connected to this study.